Form 4: ProPhase Labs Director Warren Hirsch Acquires Options
SEC Form 4 Filing
Director Warren Hirsch acquired options to purchase 100,000 shares of ProPhase Labs common stock on February 14, 2025.
Summary
- On February 14, 2025, Warren Hirsch, a director of ProPhase Labs, Inc., acquired options to purchase 100,000 shares of the company's common stock.
- The exercise price of the options is $0.60.
- The options vest in four equal installments, starting September 30, 2025, and continuing through June 30, 2026, contingent upon continued service as a non-employee director.
- The options expire on February 14, 2032.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of an insider transaction. The acquisition of options could be seen as a slightly positive signal, but it's not a major event.
Positives
- The acquisition of options by a director could be seen as a positive sign, indicating confidence in the company's future performance.
Future Outlook
The document does not contain specific forward-looking statements, but the vesting schedule of the options suggests an expectation of continued service by the director.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.
Comparison to Industry Standards
- Option grants to directors are a common form of compensation in publicly traded companies, particularly in the biotech and pharmaceutical industries.
- The vesting schedule and exercise price are typical for such grants, aligning the director's interests with those of the shareholders.
- Comparable companies such as QuidelOrtho and Exact Sciences also utilize stock options as part of their director compensation packages.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholders if it signals confidence from a director.
Key Dates
| Date | Description |
|---|---|
| 02/14/2025 | Date of the options transaction. |
| 02/14/2025 | Date of acquisition of options. |
| 09/30/2025 | First vesting date for 25% of the options. |
| 12/31/2025 | Second vesting date for 25% of the options. |
| 03/31/2026 | Third vesting date for 25% of the options. |
| 06/30/2026 | Final vesting date for 25% of the options. |
| 02/14/2032 | Expiration date of the options. |
| 02/18/2025 | Date of signature. |
Keywords
ProPhase Labs, Warren Hirsch, options, director, acquisition, PRPH, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.